Rectify Pharma Secures $100M Series A Funding to Accelerate Next-Generation PFM Therapeutics

Rectify Pharma is thrilled to announce the successful closing of its $100 million Series A funding round, a monumental achievement that underscores the company’s unique vision and breakthrough approach to healthcare innovation. At the forefront of drug discovery, Rectify Pharma is pioneering the development of Positive Functional Modulators (PFMs)—a novel class of oral, small molecules engineered to restore and enhance the function of critical membrane proteins. This innovative platform stands to revolutionize treatment strategies by not only modulating the activity of wild-type proteins but also by offering therapeutic potential for mutated membrane-bound proteins which are often at the root of serious diseases. With a focus spanning both rare and common diseases, Rectify is set to make a significant impact across challenging therapeutic landscapes including liver disorders, cardio-renal-metabolic conditions, and neurodegenerative diseases. The funding round, co-led by Atlas Venture and Omega Funds, with robust support from Forbion and Longwood Fund, is poised to accelerate Rectify’s mission of rapid and efficient discovery of first- and best-in-class small molecule candidates. The capital will be leveraged to broaden research and development initiatives, enhance clinical trial capabilities, and expand the company’s state-of-the-art technological infrastructure. By fueling innovation and expediting discovery timelines, Rectify Pharma aims to address the underlying causes of complex diseases and ultimately improve patient outcomes on a global scale. This significant financial endorsement not only validates Rectify’s scientific promise and strategic direction but also reinforces its commitment to transforming healthcare through pioneering therapeutic solutions.